<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384823</url>
  </required_header>
  <id_info>
    <org_study_id>EDP-938-001</org_study_id>
    <nct_id>NCT03384823</nct_id>
  </id_info>
  <brief_title>A Study of EDP-938 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-938 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of Food on EDP-938 Pharmacokinetics in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled study will assess the safety, tolerability,
      and pharmacokinetics of single and multiple orally administered doses of EDP-938 in healthy
      adult subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first phase assesses single ascending doses for EDP-938 (active drug or placebo) in
      healthy subjects. A &quot;fasted&quot; and &quot;fed&quot; two-part cohort will also assess food effect.

      The second phase assesses multiple ascending doses (active drug or placebo) for 7-days in
      healthy subjects.

      Each cohort within each phase will enroll a total of 8 subjects who will be randomized to
      receive EDP-938 or placebo. The cohort assessing food effect will enroll 10 subjects
      randomized to receive EDP-938 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by adverse events, physical exams, vital signs, 12-lead electrocardiograms (ECGs) and clinical lab results (including chemistry, hematology, and urinalysis).</measure>
    <time_frame>Up to 8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-938</measure>
    <time_frame>Up to 5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-938</measure>
    <time_frame>Up to 11 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-938</measure>
    <time_frame>Up to 5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-938</measure>
    <time_frame>Up to 11 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>RSV Infection</condition>
  <arm_group>
    <arm_group_label>EDP-938 SAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-938 MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-938 SAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, oral suspension, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-938 MAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, oral suspension, once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-938</intervention_name>
    <description>Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).</description>
    <arm_group_label>EDP-938 SAD Cohorts</arm_group_label>
    <arm_group_label>EDP-938 MAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to match EDP-938</description>
    <arm_group_label>EDP-938 SAD Placebo Cohort</arm_group_label>
    <arm_group_label>EDP-938 MAD Placebo Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An informed consent document signed and dated by the subject.

          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 55
             years, inclusive.

        Exclusion Criteria:

          -  Clinically relevant evidence or history of illness or disease.

          -  Pregnant or nursing females.

          -  History of febrile illness within 7 days prior to the first dose of study drug or
             subjects with evidence of active infection.

          -  A positive urine drug screen at screening or Day -1.

          -  Current tobacco smokers or use of tobacco within 3 months prior to screening.

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).

          -  History of regular alcohol consumption.

          -  Participation in a clinical trial within 30 days prior to the first dose of study
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <phone>617 607 0705</phone>
    <email>nadda@enanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc.,</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Kirk</last_name>
      <phone>913-410-2258</phone>
      <email>KirkShannon@prahs.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Dickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First-in-Human</keyword>
  <keyword>Single Ascending Dose</keyword>
  <keyword>Multiple Ascending Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

